Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 4 selected

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 1 to 50 of 1577

TitleReference numberPublishedLast updated
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA1167
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)TA1168
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophilsTA1166
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1165
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentTA1164
Nusinersen and risdiplam for treating spinal muscular atrophyTA1162
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)TA1163
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatmentTA1159
Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinomaTA1160
Sotatercept for treating pulmonary arterial hypertensionTA1161
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancerTA1158
Givinostat for treating Duchenne muscular dystrophy in people 6 years and overTA1157
Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapyTA1156
Rozanolixizumab for treating antibody-positive generalised myasthenia gravisTA1155
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesityTA1152
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatmentTA1153
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)TA1154
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancerTA1150
Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)TA1151
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myelomaTA1149
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and overTA1147
Sodium zirconium cyclosilicate for treating hyperkalaemiaTA1148
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitorsTA1146
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinomaTA1145
Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistulaHTG777
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)TA1144
Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopauseTA1143
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophilsTA1142
Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shockHTG774
Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shockHTG775
Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitationHTG772
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1140
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)TA1141
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatmentTA1139
Pegzilarginase for treating arginase-1 deficiency in people 2 years and overHST35
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancerTA1138
Molnupiravir for treating COVID-19TA1056
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19TA878
Leadless cardiac pacemaker implantation for bradyarrhythmiasHTG770
Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitationHTG771
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancerTA1136
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1137
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)TA1135
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2HST34
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myelomaTA1133
Dupilumab for treating severe chronic rhinosinusitis with nasal polypsTA1134
Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)TA1132
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1129
Obinutuzumab with mycophenolate mofetil for treating lupus nephritisTA1131
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancerTA1130

Results per page

  1. 10
  2. 25
  3. 50
  4. All